Results 31 to 40 of about 7,390 (165)

Ocrelizumab zur Behandlung der Multiplen Sklerose

, 2020
Ocrelizumab is a monoclonal antibody directed against the differentiation antigen CD20, which leads to an effective long-term depletion of lymphocytes, in particular B cells.
Goebels, Norbert, Aktas, Orhan, Albrecht, Philipp, Graf, Jonas, Hartung, Hans-Peter   +4 more
core   +1 more source

An adverse effect of Ocrelizumab treatment in a patient with multiple sclerosis: a case report of necrotizing periodontitis [PDF]

, 2023
Multiple Sclerosis (MS) and Necrotizing Periodontitis (NP) are two diseases whose aetiologies and pathophysiologies do not appear to have a common link; however, treating MS with monoclonal antibodies and the decrease in humoral immunity that this ...
Jornet García, Alfonso Felipe, Montoya Carralero, José María, Sánchez Pérez, Arturo Joaquín, Moya Villaescusa, María José   +3 more
core   +1 more source

Ocrelizumab treatment in multiple sclerosis:A Danish population-based cohort study [PDF]

, 2022
Background and purpose: Real-world evidence regarding the effectiveness and safety of ocrelizumab for the treatment of multiple sclerosis (MS) is limited.
Blinkenberg, Morten, Henrik K. Mathiesen, Jensen, Michael B., Rasmussen, Peter V., Peter V. Rasmussen, Jonas M. Berg, Finn Sellebjerg, Mathiesen, Henrik K., Luigi Pontieri, Viktoria Papp, Michael B. Jensen, Papp, Viktoria, Kopp, Tine I., Stephan Bramow, Hanna Joensen, Bramow, Stephan, Pontieri, Luigi, Sirakov, Georgi, Jakob Schäfer, Berg, Jonas M., Kant, Matthias, Schäfer, Jakob, Magyari, Melinda, Morten Blinkenberg, Georgi Sirakov, Joensen, Hanna, Tine I. Kopp, Sellebjerg, Finn, Matthias Kant, Melinda Magyari   +29 more
core   +1 more source

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

, 2017
BACKGROUND: B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells.
Comi, G, Hauser, SL, Bar-Or, A, Selmaj, K, Hemmer, B, Lublin, F, Montalban, X, Giovannoni, G, Hartung, H-P, Rammohan, KW   +9 more
core   +2 more sources

Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023
Background There is limited knowledge about T cell responses in patients with multiple sclerosis (MS) after 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine.
Sarah Conway, Shrishti Saxena, Clare Baecher-Allan, Rajesh Krishnan, Maria Houtchens, Bonnie Glanz, Taylor J Saraceno, Mariann Polgar-Turcsanyi, Gauruv Bose, Rohit Bakshi, Shamik Bhattacharyya, Kristin Galetta, Tamara Kaplan, Christopher Severson, Tarun Singhal, Lynn Stazzone, Jonathan Zurawski, Anu Paul, Howard L Weiner, Brian C Healy, Tanuja Chitnis   +20 more
doaj   +1 more source

Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America

Arquivos de Neuro-Psiquiatria, 2021
Background: Despite the abundance of information concerning ocrelizumab in phase III clinical trials, there is scarce evidence regarding real-world patient profiles.
Juan Ignacio ROJAS, Liliana PATRUCCO, Manuel FRUNS, Giesela HORNUNG, José FLORES, Edgar CARNERO CONTENTTI, Pablo Adrian LOPEZ, Juan Pablo PETTINICCHI, Alejandro CARIDE, Lorna GALLEGUILLOS, Jorge BARAHONA, Violeta DIAZ, Marianella HERNÁNDEZ, Ricardo ALONSO, Edgardo CRISTIANO   +14 more
doaj   +1 more source

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022
Background Ocrelizumab is a monoclonal antibody targeting CD20-expressing B cells used in the treatment of multiple sclerosis (MS). Currently, there is limited safety data in pregnancy.
Shin Yee Chey, Allan G. Kermode
doaj   +1 more source

Risk of infection in ocrelizumab-treated adults with multiple sclerosis aged 55 years and older: a retrospective cohort study

The Lancet Regional Health. Americas
Summary: Background: Pivotal trials for ocrelizumab in multiple sclerosis (MS) excluded adults >55 years old. This study aimed to compare rates of infection and infection-related hospitalization between ocrelizumab-treated and unexposed older adults with
Seungwon Lee, Raphael Scheu, Nomin Enkhtsetseg, Justin Hill, Joseph Sadok, Maya Mastick, Siddharth Satish, Farrah J. Mateen   +7 more
doaj   +1 more source

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials

Scientific Reports, 2023
Ocrelizumab is a B cell-depleting drug widely used in relapsing–remitting multiple sclerosis (RRMS) and primary-progressive MS. In RRMS, it is becoming increasingly apparent that accumulation of disability not only manifests as relapse-associated ...
J. Ingwersen, L. Masanneck, M. Pawlitzki, S. Samadzadeh, M. Weise, O. Aktas, S. G. Meuth, P. Albrecht   +7 more
doaj   +1 more source

An Unexpected Post-ocrelizumab Improvement in Glycaemic Control in a Patient with Multiple Sclerosis

European Medical Journal Diabetes, 2022
Ocrelizumab, a novel member of disease-modifying therapies for multiple sclerosis (MS), is a humanised monoclonal antibody against the CD20 molecule on the surface of B cells.
Ozge Arici Duz, Sebnem Bektas, Abdullah Emre Askin, Erkingul Birday   +3 more
doaj   +1 more source